Conclusions Early use of PARPis in the therapeutic course of platinum-sensitive ovarian cancer was recommended in the gBRCA mutation cohort. Niraparib is a promising candidate for next front-line maintenance therapy in such patients. Legal entity responsible for the study The author. Funding The ...
Small-cell lung cancer (SCLC) is a deadly cancer associated with smoke exposure that has neuroendocrine (NE) cell properties and is pathologically, molecularly, biologically and clinically very different from other lung cancers. While most patients with SCLC respond initially to cytotoxic therapy, almo...
LYNPARZA is a targeted therapy that works by targeting cancer cell pathways. It is a poly(ADP-ribose)polymerase inhibitor, also referred to as aPARP inhibitor. PARP helps cells, including cancer cells, survive and grow PARP is a protein that helps repair DNA damage in cells so they can su...
Although the use of PARP inhibitors is a huge step forward, it is apparent that patients, both with and without BRCA-mutant ovarian cancer, will eventually become resistant to PARP inhibitors. Therefore, novel combination therapies may enhance PARP inhibitor efficacy and overcome resistance mechanisms...
They also showed that cells deficient in RAD51D appeared to be sensitive to treatment with PARP inhibitor, thus posing a possible therapeutic approach for cancers arising in RAD51D mutation carriers [47]. Furthermore, genomic variations at multiple loci encoding proteins which biologically interact ...
DNA-bound proteins pose a physical challenge to all types of DNA transactions and are therefore harmful to cells. Thus, knowing how DPCs form in different situations, the consequences of DPCs, how cells deal with DPCs, and how we can use the underlying knowledge for cancer therapy is ...
This suggests that other structural changes occur upon inhibitor binding to the PSMA active site, resulting in unavailability of the binding site for the bicyclic peptide. We conclude that Peptide 1 and the corresponding iBody 1 likely bind outside of the active site to an exosite that is only...
correlate with a poor prognosis.102–104 Likewise, amplifications of MDM2 and CCND1 (cyclin D1), although uncommon in GISTs, are associated with malignancy.105 Kinase mutations and tyrosine kinase inhibitor therapy Until the year 2000, treatment options for patients with advanced GIST were poor. ...
“When I started as an oncology nurse 10 years ago, an ovarian cancer diagnosis was a very grave discussion, but now, it’s more optimistic,” said Arn. “With maintenance therapy, if an individual is HRD positive using a PARP inhibitor, we are seeing much longer interv...
One such promising regimen is R-CHOP in combination with the proteasome inhibitor bortezomib. This regimen is being evaluated in nongerminal center B-cell (non-GCB)-like tumors, based on the observation that nuclear factor-kappa B (NF-κB) transcriptional activity is upregulated in this subtype...